<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[HitGen Ltd 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=30735></link><description><![CDATA[HitGen Ltd 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Sat, 16 May 2026 11:30:44 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2018/04/3698601005_20180424193320_4216972744.jpg]]></url></image><language>ko-KR</language><item><title><![CDATA[HitGen Announces Research Collaboration and License Agreement with Simcere]]></title><link>https://www.newswire.co.kr/newsRead.php?no=868211</link><description><![CDATA[CHENGDU, China--(Business Wire/Korea Newswire)--Simcere Pharmaceutical Group (Simcere) and HitGen Ltd (HitGen) announced today that they have entered into a license agreement on innovative drug discovery.  Based on the multi-year research collaboration agreement previously signed between two parties, HitGen has identified several novel and active small molecule leads by using its leading tech...]]></description><pubDate>Tue, 24 Apr 2018 19:40:00 +0900</pubDate></item><item><title><![CDATA[히트젠, 심시어와 연구 협력 및 라이선스 계약 체결]]></title><link>https://www.newswire.co.kr/newsRead.php?no=868212</link><description><![CDATA[청두, 중국--(Business Wire/뉴스와이어)--심시어 파마슈티컬 그룹(Simcere Pharmaceutical Group, 이하 ‘심시어’)과 히트젠(HitGen Ltd)이 혁신적인 신약 개발에 관한 라이선스 계약을 체결했다고 23일 발표했다.  히트젠은 예전에 양측이 서명한 다년간의 연구 협력 계약에 기반을 두고 주요 기술 플랫폼을 사용해 몇 가지 새로운 활성 소분자 물질들을 확인했다. 이는 화학적으로 다양한 구조물에서 합성된 약 유...]]></description><pubDate>Tue, 24 Apr 2018 19:40:00 +0900</pubDate></item></channel></rss>